循证新视角——原研替奈普酶治疗急性缺血性卒中安全性的多维验证_原研替奈普酶_卒中

循证新视角——原研替奈普酶治疗急性缺血性卒中安全性的多维验证

2025-06-05 来源：医脉通

关键词：原研替奈普酶卒中

发表评论

微信图片_202506131347151.jpg

审批编码：SC-CN-16772

有效期至：2026年5月27日

仅供相关医药专业人士进行医学科学交流

参考文献

                                                                1.Tanswell P, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41(15):1229-1245.                                                            

                                                                2.Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-722.                                                            

                                    3.中国医师协会神经内科医师分会脑血管病专家组. 急性缺血性卒中替奈普酶静脉溶栓治疗中国专家共识. 中国神经精神疾病杂志,2022,48(11):641-651.                                
                                                            
                                                                4.Menon BK, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.                                                            

                                                                5.Muir KW, et al. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol. 2024;23(11):1087-1096.                                                            

                                                                6.Parsons MW, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol. 2024;23(8):775-786.                                                            

                                                                7.Meng X, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024;332(17):1437-1445.                                                            

                                                                8.Palaiodimou L, et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. Neurology. 2024;103(9):e209903.                                                            

                                                                9.Warach SJ, et al. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. JAMA Neurol. 2023;80(7):732-738.                                                            

                                                                10.Rousseau JF, et al. Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke. JAMA Netw Open. 2025;8(3):e250548.